Cargando…

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffett, Kristine, Welch, Ryan D., Flaveny, Colin A., Kolar, Grant R., Neuschwander-Tetri, Brent A., Burris, Thomas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354919/
https://www.ncbi.nlm.nih.gov/pubmed/25830098
http://dx.doi.org/10.1016/j.molmet.2015.01.009
_version_ 1782360802284535808
author Griffett, Kristine
Welch, Ryan D.
Flaveny, Colin A.
Kolar, Grant R.
Neuschwander-Tetri, Brent A.
Burris, Thomas P.
author_facet Griffett, Kristine
Welch, Ryan D.
Flaveny, Colin A.
Kolar, Grant R.
Neuschwander-Tetri, Brent A.
Burris, Thomas P.
author_sort Griffett, Kristine
collection PubMed
description OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepatic steatosis. We hypothesized that suppression of lipogenesis, which is pathologically elevated in NASH may suppress progression of hepatic steatosis to NASH. METHODS: NASH was induced in B6 V-lep (ob)/J (ob/ob) mice using a custom complete rodent diet (HTF) containing high amounts of trans-fat, fructose, and cholesterol. Once NASH was induced, mice were treated with SR9238 for one month by i.p. injection. Plasma lipid levels and liver health were analyzed by clinical chemistry. QPCR, western blot, and immunohistochemistry were used to assess disease severity. RESULTS: Ob/ob mice are obese and diabetic thus they are commonly used as models for the study of metabolic diseases. These mice quickly developed the NASH phenotype when provided the HTF diet. The mice develop hepatic steatosis, severe hepatic inflammation and fibrosis on the HTF diet. Treatment with SR9238 significantly reduced the severity of hepatic steatosis and most importantly reduced hepatic inflammation and ameliorated hepatic fibrosis. CONCLUSIONS: Here, we demonstrate that an LXR inverse agonist, SR9238, is effective in reduction of hepatic steatosis, inflammation and fibrosis in an animal model of NASH. These results have important implications for the development of therapeutics for treatment NASH in humans.
format Online
Article
Text
id pubmed-4354919
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-43549192015-03-31 The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis Griffett, Kristine Welch, Ryan D. Flaveny, Colin A. Kolar, Grant R. Neuschwander-Tetri, Brent A. Burris, Thomas P. Mol Metab Brief Communication OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepatic steatosis. We hypothesized that suppression of lipogenesis, which is pathologically elevated in NASH may suppress progression of hepatic steatosis to NASH. METHODS: NASH was induced in B6 V-lep (ob)/J (ob/ob) mice using a custom complete rodent diet (HTF) containing high amounts of trans-fat, fructose, and cholesterol. Once NASH was induced, mice were treated with SR9238 for one month by i.p. injection. Plasma lipid levels and liver health were analyzed by clinical chemistry. QPCR, western blot, and immunohistochemistry were used to assess disease severity. RESULTS: Ob/ob mice are obese and diabetic thus they are commonly used as models for the study of metabolic diseases. These mice quickly developed the NASH phenotype when provided the HTF diet. The mice develop hepatic steatosis, severe hepatic inflammation and fibrosis on the HTF diet. Treatment with SR9238 significantly reduced the severity of hepatic steatosis and most importantly reduced hepatic inflammation and ameliorated hepatic fibrosis. CONCLUSIONS: Here, we demonstrate that an LXR inverse agonist, SR9238, is effective in reduction of hepatic steatosis, inflammation and fibrosis in an animal model of NASH. These results have important implications for the development of therapeutics for treatment NASH in humans. Elsevier 2015-02-09 /pmc/articles/PMC4354919/ /pubmed/25830098 http://dx.doi.org/10.1016/j.molmet.2015.01.009 Text en © 2015 Elsevier GmbH. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Communication
Griffett, Kristine
Welch, Ryan D.
Flaveny, Colin A.
Kolar, Grant R.
Neuschwander-Tetri, Brent A.
Burris, Thomas P.
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title_full The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title_fullStr The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title_full_unstemmed The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title_short The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
title_sort lxr inverse agonist sr9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354919/
https://www.ncbi.nlm.nih.gov/pubmed/25830098
http://dx.doi.org/10.1016/j.molmet.2015.01.009
work_keys_str_mv AT griffettkristine thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT welchryand thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT flavenycolina thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT kolargrantr thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT neuschwandertetribrenta thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT burristhomasp thelxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT griffettkristine lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT welchryand lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT flavenycolina lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT kolargrantr lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT neuschwandertetribrenta lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis
AT burristhomasp lxrinverseagonistsr9238suppressesfibrosisinamodelofnonalcoholicsteatohepatitis